What's Happening?
Surf Therapeutics, a clinical-stage company based in Austin, Texas, has announced positive results from its first-in-human study on non-invasive ultrasound neuromodulation therapies aimed at treating immune-mediated diseases. The study, which involved
14 participants with inflammatory arthritis, demonstrated significant reductions in pro-inflammatory cytokines TNF-α and IL-6, with no adverse events reported. Following these promising results, Surf Therapeutics has closed an extension seed financing round, bringing its total funding to approximately $6 million. The company plans to publish the study data later this year and present its findings at the EULAR 2026 conference. This funding will support the advancement of their clinical evidence and preparation for a future pivotal trial.
Why It's Important?
The successful study and subsequent funding boost for Surf Therapeutics highlight the potential of non-invasive therapies in treating autoimmune diseases like rheumatoid arthritis. This development is significant as it offers a promising alternative to traditional pharmaceutical treatments, which often come with side effects and high costs. The ability to reduce inflammation through ultrasound neuromodulation could revolutionize treatment approaches, providing patients with safer, at-home therapy options. The financial backing from notable investors underscores confidence in Surf Therapeutics' innovative approach and its potential impact on the healthcare industry, particularly in the field of autoimmune disease management.
What's Next?
Surf Therapeutics is set to continue its research and development efforts, with plans to initiate a pivotal trial for its ultrasound neuromodulation therapy. The company has already begun enrolling patients in its SUSTAIN early feasibility study across clinical sites in the Dallas–Fort Worth area. As the company progresses, it aims to further validate its technology and prepare for commercial scalability. The upcoming publication of study data and presentations at major conferences will be crucial in garnering further support and interest from the medical community and potential investors.
